分享产品介绍 评论(0)
物种
Human分子别名
Tumor necrosis factor ligand superfamily member 13, A proliferation-inducing ligand (APRIL), TNF- and APOL-related leukocyte expressed ligand 2 (TALL-2), TNF-related death ligand 1 (TRDL-1), CD256Accession
O75888表达序列
Gln111-Leu250
表达宿主
HEK293分子量
18-20 kDa (Reducing)
纯度
>95% by SDS-PAGE; >90% by HPLC.内毒素含量
<0.1EU/μg活性
EC50 = 17.1-25.9 ng/ml标记
Unconjugated标签
No Tag性状
Lyophilized Powder缓冲体系
20mM Tris, 300mM NaCl, pH8.0
溶解方法
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
储存条件
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.文献引用
Nature. 2021 Sep;597(7874):92-96.
Nat Immunol. 2000 Sep;1(3):252-6.
APRIL (A Proliferation-Inducing Ligand), also known as TNFSF13, is a member of the tumor necrosis factor (TNF) superfamily encoded by the TNFSF13 gene located on human chromosome 17p13. This 250-amino acid type II transmembrane protein functions as a homotrimeric cytokine and plays pivotal roles in immune regulation, B cell biology, and various pathological conditions including cancer, autoimmune diseases, and cardiovascular disorders.
APRIL is extensively studied in systemic lupus erythematosus (SLE), Sjögren's syndrome, IgA nephropathy, and rheumatoid arthritis. Elevated APRIL levels correlate with disease activity, making it a therapeutic target. Atacicept (TACI-Ig fusion protein) neutralizes both APRIL and BAFF, showing promise in clinical trials.
电泳
2μg (R: reducing condition, N: non-reducing condition).
反相高效液相色谱(RP-HPLC)
>90% as determined by RP-HPLC.
ELISA
Immobilized APRIL/TNFSF13 Protein, Human (Cat. No. UA040509) at 2.0μg/mL (100μL/well) can bind TACI/CD267/TNFRSF13B Fc Chimera Protein, Human (Cat. No. UA011118) with EC50 of 17.09-25.91 ng/mL.
评论(0)